These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35053311)

  • 1. Super-Enhancers Dysregulations in Hematological Malignancies.
    Belloucif Y; Lobry C
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.
    Jia Y; Chng WJ; Zhou J
    J Hematol Oncol; 2019 Jul; 12(1):77. PubMed ID: 31311566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Super-enhancers in cancer.
    Thandapani P
    Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular understanding of super-enhancer dysregulation in cancer.
    Yoshino S; Suzuki HI
    Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies.
    Dębek S; Juszczyński P
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188697. PubMed ID: 35150791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ Super-enhancers. Are they regulators of regulatory genes of development and cancer?].
    Didych DA; Tyulkina DV; Pleshkan VV; Alekseenko IV; Sverdlov ED
    Mol Biol (Mosk); 2015; 49(6):915-22. PubMed ID: 26710770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Super-enhancers in transcriptional regulation and genome organization.
    Wang X; Cairns MJ; Yan J
    Nucleic Acids Res; 2019 Dec; 47(22):11481-11496. PubMed ID: 31724731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.
    Guillaumet-Adkins A; Richter J; Odero MD; Sandoval J; Agirre X; Catala A; Esteller M; Prósper F; Calasanz MJ; Buño I; Kwon M; Court F; Siebert R; Monk D
    J Hematol Oncol; 2014 Jan; 7():4. PubMed ID: 24405639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Understanding of molecular pathogenesis of T-cell leukemia by super-enhancer profiling].
    Sanda T
    Rinsho Ketsueki; 2018; 59(7):899-908. PubMed ID: 30078801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting Tissue-Specific Super-Enhancers by Integrating Genome-Wide Analyses and CRISPR/Cas9 Genome Editing.
    Yoo KH; Hennighausen L; Shin HY
    J Mammary Gland Biol Neoplasia; 2019 Mar; 24(1):47-59. PubMed ID: 30291498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiology of super-enhancer reprogramming and activation in cancer.
    Zhou RW; Parsons RE
    Epigenetics Chromatin; 2023 Jul; 16(1):29. PubMed ID: 37415185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms.
    Jia Q; Chen S; Tan Y; Li Y; Tang F
    Exp Mol Med; 2020 May; 52(5):713-723. PubMed ID: 32382065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape.
    Zhou Z; Li J; Ousmane D; Peng L; Yuan X; Wang J
    Mol Ther; 2024 Mar; 32(3):572-579. PubMed ID: 38327048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancers and MYC interplay in hematopoiesis.
    Benetatos L; Benetatou A; Vartholomatos G
    J Mol Med (Berl); 2020 Apr; 98(4):471-481. PubMed ID: 32144465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
    Bacabac M; Xu W
    Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super-enhancers and novel therapeutic targets in colorectal cancer.
    Liu Q; Guo L; Lou Z; Xiang X; Shao J
    Cell Death Dis; 2022 Mar; 13(3):228. PubMed ID: 35277481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.
    Wang C; Zhang L; Ke L; Ding W; Jiang S; Li D; Narita Y; Hou I; Liang J; Li S; Xiao H; Gottwein E; Kaye KM; Teng M; Zhao B
    Nat Commun; 2020 Dec; 11(1):6318. PubMed ID: 33298918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
    Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
    Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The functions and clinical significance of circRNAs in hematological malignancies.
    Zhou X; Zhan L; Huang K; Wang X
    J Hematol Oncol; 2020 Oct; 13(1):138. PubMed ID: 33069241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
    Nakagawa M; Kitabayashi I
    Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.